PLX
Protalix BioTherapeutics Inc.

16,423
Loading...
Loading...
News
all
press releases
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.
Stocktwits·5mo ago
News Placeholder
More News
News Placeholder
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference PR Newswire CARMIEL, Israel, Feb...
PR Newswire·8mo ago
News Placeholder
Pluxee shares jump 11% on strong Q1 operating revenue growth
Investing.com -- Pluxee NV (EPA:PLX) reported 12.1% organic growth in first-quarter operating revenue, beating market expectations, and sending its shares soaring 11% in European trading Wednesday.
investing.com·9mo ago
News Placeholder
Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE: PLX) (Protalix) on behalf of the companys shareholders. Since May 2023, shares of Protalix common stock have...
Business Wire·1y ago
News Placeholder
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference...
PR Newswire·1y ago

Latest PLX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.